2-amino-6-bromo-8-isopropyl-4-methylpteridin-7(8H)-one | 1184916-06-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 蝶啶及其衍生物
• 英文名称: 2-amino-6-bromo-8-isopropyl-4-methylpteridin-7(8H)-one
• 英文别名: 2-amino-6-bromo-4-methyl-8-propan-2-ylpteridin-7-one
• CAS: 1184916-06-0
• 化学式: C₁₀H₁₂BrN₅O
• 分子量: 298.142
• InChiKey: KSEXJWDVOBFVRY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  17
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  84.5
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  2-amino-6-bromo-8-isopropyl-4-methylpteridin-7(8H)-one 、 alkaline earth salt of/the/ methylsulfuric acid 在 bis-triphenylphosphine-palladium(II) chloride 、 potassium carbonate 作用下， 以 水 、 N,N-二甲基甲酰胺 为溶剂， 生成 2-amino-8-isopropyl-4-methyl-6-(1H-pyrazol-5-yl)pteridin-7(8H)-one
  参考文献：
  名称：

  4-Methylpteridinones as orally active and selective PI3K/mTOR dual inhibitors

  摘要：

  Pteridinones were designed based on a non-selective kinase template. Because of the uniqueness of the PI3K and mTOR binding pockets, a methyl group was introduced to C-4 position of the peteridinone core to give compounds with excellent selectivity for PI3K and mTOR. This series of compounds were further optimized to improve their potency against PI3K alpha and mTOR. Finally, orally active compounds with improved solubility and robust in vivo efficacy in tumor growth inhibition were identified as well. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2010.08.045
• 作为产物：
  描述：

  2-amino-8-isopropyl-4-methylpteridin-7(8H)-one 在 N-溴代丁二酰亚胺(NBS) 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 生成 2-amino-6-bromo-8-isopropyl-4-methylpteridin-7(8H)-one
  参考文献：
  名称：

  4-Methylpteridinones as orally active and selective PI3K/mTOR dual inhibitors

  摘要：

  Pteridinones were designed based on a non-selective kinase template. Because of the uniqueness of the PI3K and mTOR binding pockets, a methyl group was introduced to C-4 position of the peteridinone core to give compounds with excellent selectivity for PI3K and mTOR. This series of compounds were further optimized to improve their potency against PI3K alpha and mTOR. Finally, orally active compounds with improved solubility and robust in vivo efficacy in tumor growth inhibition were identified as well. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2010.08.045